A
Actinium Pharmaceuticals, Inc. (ATNM)
ASE – Real vaqt narxi. Valyuta: USD
0.99
+0.04 (4.21%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.99
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:05 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
ASE – Real vaqt narxi. Valyuta: USD
0.99
+0.04 (4.21%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
0.99
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:05 PM EDT
Actinium Pharmaceuticals, Inc. o'tkir onkologik davolash usullari samara bermagan odamlar uchun natijalarni yaxshilashga qaratilgan antitel-radiatsiya kon'yugatlarini va boshqa maqsadli radioterapiyalarni ishlab chiqadi. Kompaniya taqdim etadi Actimab-A, bu relapsli/refrakter AML bemorlari uchun CD33-ni nishonga oladigan radioterapiya bo'lib, u 2/3-fazali sinovlarda; va Iomab-ACT, bu sil kasali kabi gematologik kasalliklar uchun CAR-T va gen terapiyalari kabi hujayra terapiyalariga bemorlar kirishini va natijalarini yaxshilashga qaratilgan. Shuningdek, u prostata saratoni hujayralariga alfa-emitent Ac-225 ni yetkazib beruvchi antitel-radiatsiya kon'yugati ATNM-400 ni ishlab chiqadi. Bundan tashqari, kompaniyaning Iomab-B relapsli va refrakter o'tkir miyeloid leykemiyasi bo'lgan bemorlarda suyak iligi transplantatsiyasi oldidan induksiya va konditsioner vosita hisoblanadi. Shuningdek, u Milliy saraton instituti bilan AML va boshqa miyeloid malignliklarda Actimab-A ni ishlab chiqish bo'yicha hamkorlikdagi tadqiqot va ishlab chiqish shartnomasi doirasida hamkorlik qiladi va uning tadqiqot va ishlab chiqish faoliyati asosan qattiq o'smalar uchun turli preklinik dasturlarni ilgari surishga qaratilgan. Kompaniya Nyu-York shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Madhuri Vusirikala M.D. | Vice President of Clinical Development BMT & Cellular Therapy |
| Dr. Paul Diamond Esq., Ph.D. | Vice President of Patent & Legal Counsel |
| Dr. Steffen Heeger M.D., M.Sc., Ph.D. | Chief Medical Officer |
| Mr. Sandesh C. Seth M.B.A., M.S. | CEO, Principal Financial Officer & Chairman |
| Ms. Lynn M. Bodarky M.B.A. | Chief Business Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-18 | 8-K | ea0295259-8k_actinium.htm |
| 2026-05-29 | 8-K | ea0292691-8k_actinium.htm |
| 2026-05-08 | 10-Q | ea0286467-10q_actinium.htm |
| 2026-03-30 | 10-K | ea0279291-10k_actinium.htm |
| 2026-03-26 | 8-K/A | ea028303901-8ka_actinium.htm |
| 2026-02-13 | 8-K | ea0277127-8k_actinium.htm |
| 2025-11-26 | 8-K | ea026750301-8k_actinium.htm |
| 2025-11-14 | 10-Q | ea0262047-10q_actinium.htm |
| 2025-11-05 | DEF 14A | ea0260530-01.htm |
| 2025-11-05 | ARS | ea0260530-03.pdf |